首页> 外文期刊>Allergy >Detailed characterization of Act d 12 and Act d 13 from kiwi seeds: Implication in IgE cross-reactivity with peanut and tree nuts
【24h】

Detailed characterization of Act d 12 and Act d 13 from kiwi seeds: Implication in IgE cross-reactivity with peanut and tree nuts

机译:猕猴桃种子第12号法和第13号法的详细表征:与花生和坚果在IgE交叉反应中的意义

获取原文
获取原文并翻译 | 示例
       

摘要

Background Act d 12 (11S globulin) and Act d 13 (2S albumin) are two novel relevant allergens from kiwi seeds that might be useful to improve the diagnostic sensitivity and the management of kiwifruit-allergic patients.Objective To perform a comprehensive structural and immunological characterization of purified Act d 12 and Act d 13 from kiwi seeds.Methods Sera from 55 well-defined kiwifruit-allergic patients were used. Act d 12 and Act d 13 were purified by chromatographic procedures. Circular dichroism, mass spectrometry, concanavalin A detection, immunoblotting, enzyme-linked immunosorbent assays, basophil activation tests, and IgE-inhibition experiments were used.Results Act d 12 and Act d 13 were purified from kiwi seeds to homogeneity by combining size-exclusion, ion-exchange, and RP-HPLC chromatographies. Both purified allergens preserve the structural integrity and display typical features of their homologous counterparts from the 11S globulin and 2S albumin protein families, respectively. These allergens are released from kiwi seeds after oral and gastric digestion of whole kiwifruit, demonstrating their bioavailability after ingestion. The allergens retain the capacity to bind serum IgE from kiwifruit-allergic patients, induce IgE cross-linking in effector-circulating basophils, and display in vitro IgE cross-reactivity with homologous counterparts from peanut and tree nuts.Conclusion Purified Act d 12 and Act d 13 from kiwi seeds are well-defined molecules involved in in vitro IgE cross-reactivity with peanut and tree nuts. Their inclusion in component-resolved diagnosis of kiwifruit allergy might well contribute to improve the diagnostic sensitivity and the management of kiwifruit-allergic patients.
机译:背景d 12(11S球蛋白)法和d 13(2S白蛋白)法是来自奇异果种子的两种新的相关过敏原,可能有助于提高奇异果过敏患者的诊断敏感性和管理水平。目的进行全面的结构和免疫学研究猕猴桃种子中纯化的Act d 12和Act d 13的特征分析。方法使用55名明确的猕猴桃过敏患者的血清。通过色谱法纯化Act d 12和Act d 13。采用圆二色谱,质谱,伴刀豆球蛋白A检测,免疫印迹,酶联免疫吸附试验,嗜碱性粒细胞活化试验和IgE抑制实验。结果结合大小排阻法,从猕猴桃种子中纯化出Act d 12和Act d 13同质。 ,离子交换和RP-HPLC色谱。两种纯化的过敏原均保留其结构完整性,并分别显示其来自11S球蛋白和2S白蛋白蛋白家族的同源对应物的典型特征。口服和胃消化整个猕猴桃后,这些过敏原会从猕猴桃种子中释放出来,表明它们在摄入后具有生物利用度。过敏原保留了结合猕猴桃过敏患者血清IgE的能力,在循环效应子的嗜碱性粒细胞中诱导IgE交联,并与花生和坚果的同源异种表现出体外IgE交叉反应性。结论纯化法12和法来自猕猴桃的d 13是明确定义的分子,涉及与花生和坚果的体外IgE交叉反应。将其包含在奇异果过敏的成分分辨诊断中可能很好地有助于提高奇异果过敏患者的诊断敏感性和管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号